Markus Warmuth, Monte Rosa CEO

Monte Rosa takes this week's IPO lead as a nine-fig­ure raise push­es in­dus­try to­tal past $9B

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Ma­jor League Base­ball isn’t the on­ly in­dus­try that’s un­der­go­ing a reck­on­ing over “sticky stuff,” as Monte Rosa Ther­a­peu­tics takes its mol­e­c­u­lar glues pub­lic Thurs­day ready to shake up Nas­daq.

The Boston-based biotech priced its IPO late Wednes­day night and plans to start trad­ing Thurs­day at a launch price of $19 per share. Monte Rosa se­cured $222.3 mil­lion with the of­fer­ing as biotech con­tin­ues its record IPO pace: now with 54 com­pa­nies go­ing pub­lic in 2021, the in­dus­try is on track to see more than 100 de­buts in a cal­en­dar year for the first time ever, ac­cord­ing to the End­points News tal­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.